Fig. 8: Osteopontin levels are increased in patient-matched recurrent metastatic tumors versus primary breast tumors.
From: Osteopontin is a therapeutic target that drives breast cancer recurrence
a Sample manifest of patient-matched primary breast tumors and recurrent metastatic tumors. b Fluorescent IHC for OPN, PanCK, and DAPI on patient-matched primary breast tumors (n = 10) and recurrent metastatic tumors (n = 10). c–e Quantification of OPN H Score, total OPN+ cells, and OPN+ PanCK+ cells in patient-matched primary breast tumors (n = 10) and recurrent metastatic tumors (n = 10). Scale bars are as indicated on each image. Mean ± SEM for data calculated using two-tailed Student’s t test. Each data point is representative of one biological sample for (c–e). Source data are provided as a Source Data file.
